Los Angeles Capital Management & Equity Research Inc. boosted its stake in shares of PAREXEL International Corporation (NASDAQ:PRXL) by 21.0% during the first quarter, Holdings Channel reports. The firm owned 4,063 shares of the medical research company’s stock after buying an additional 704 shares during the period. Los Angeles Capital Management & Equity Research Inc.’s holdings in PAREXEL International Corporation were worth $256,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Russell Investments Group Ltd. purchased a new position in shares of PAREXEL International Corporation during the fourth quarter valued at approximately $1,638,000. Comerica Bank raised its position in shares of PAREXEL International Corporation by 7.9% in the fourth quarter. Comerica Bank now owns 42,391 shares of the medical research company’s stock valued at $3,020,000 after buying an additional 3,094 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in shares of PAREXEL International Corporation by 0.8% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 7,886 shares of the medical research company’s stock valued at $518,000 after buying an additional 63 shares during the period. Martingale Asset Management L P raised its position in shares of PAREXEL International Corporation by 15.9% in the fourth quarter. Martingale Asset Management L P now owns 43,008 shares of the medical research company’s stock valued at $2,827,000 after buying an additional 5,902 shares during the period. Finally, Federated Investors Inc. PA raised its position in shares of PAREXEL International Corporation by 0.8% in the fourth quarter. Federated Investors Inc. PA now owns 29,896 shares of the medical research company’s stock valued at $1,965,000 after buying an additional 229 shares during the period. Hedge funds and other institutional investors own 97.69% of the company’s stock.

Institutional Ownership by Quarter for PAREXEL International Corporation (NASDAQ:PRXL)

PAREXEL International Corporation (NASDAQ:PRXL) opened at 83.92 on Tuesday. PAREXEL International Corporation has a 52-week low of $51.16 and a 52-week high of $84.06. The company’s 50-day moving average price is $78.07 and its 200 day moving average price is $68.38. The company has a market capitalization of $4.26 billion, a price-to-earnings ratio of 36.89 and a beta of 0.80.

PAREXEL International Corporation (NASDAQ:PRXL) last issued its quarterly earnings data on Wednesday, May 3rd. The medical research company reported $0.74 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.01. PAREXEL International Corporation had a return on equity of 28.68% and a net margin of 5.12%. The company had revenue of $529.30 million for the quarter, compared to analysts’ expectations of $529.38 million. During the same period in the previous year, the firm posted $0.89 earnings per share. The firm’s revenue for the quarter was up .4% on a year-over-year basis. On average, equities analysts expect that PAREXEL International Corporation will post $3.24 EPS for the current fiscal year.

WARNING: “PAREXEL International Corporation (PRXL) Position Increased by Los Angeles Capital Management & Equity Research Inc.” was published by Daily Political and is the sole property of of Daily Political. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/06/20/parexel-international-corporation-prxl-position-increased-by-los-angeles-capital-management-equity-research-inc.html.

Several equities analysts have recently commented on PRXL shares. Mizuho started coverage on PAREXEL International Corporation in a research report on Thursday, March 23rd. They set a “neutral” rating and a $86.00 price objective on the stock. Zacks Investment Research upgraded PAREXEL International Corporation from a “sell” rating to a “hold” rating in a research report on Wednesday, April 5th. Evercore ISI upgraded PAREXEL International Corporation from an “in-line” rating to an “outperform” rating and set a $85.00 price objective on the stock in a research report on Monday, May 15th. Barclays PLC reiterated an “overweight” rating and set a $87.00 price objective on shares of PAREXEL International Corporation in a research report on Wednesday, May 17th. Finally, Goldman Sachs Group, Inc. (The) upgraded PAREXEL International Corporation from a “sell” rating to a “neutral” rating and increased their price objective for the company from $63.00 to $77.00 in a research report on Tuesday, May 23rd. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $72.83.

About PAREXEL International Corporation

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Want to see what other hedge funds are holding PRXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PAREXEL International Corporation (NASDAQ:PRXL).

Receive News & Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related companies with MarketBeat.com's FREE daily email newsletter.